3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Sezary Syndrome
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
34
fludarabine phosphate
33
Cytarabine
33
fludarabine
26
Peripheral Blood Stem Cell Transplantation
23
Filgrastim
23
Methotrexate
18
Busulfan
17
Rituximab
15
Cyclosporine
14
Azacitidine
14
Melphalan
13
Clofarabine
13
Tacrolimus
12
venetoclax
11
Mycophenolic Acid
10
Etoposide
10
Alemtuzumab
10
Radiotherapy
9
Imatinib Mesylate
8
Granulocyte Colony-Stimulating Factor
8
Decitabine
8
ruxolitinib
7
Whole-Body Irradiation
7
Stem Cell Transplantation
7
Idarubicin
7
Dexamethasone
7
Antilymphocyte Serum
7
aldesleukin
6
Mitoxantrone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia
×
navitoclax
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn